References
- Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–703. doi:https://doi.org/10.1016/S0140-6736(64)91524-7.
- Henle G, Henle W, Diehl V. Relation of Burkitt’s tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci U S A. 1968;59(1):94–101. doi:https://doi.org/10.1073/pnas.59.1.94.
- Balfour HH, Odumade OA, Schmeling DO, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013;207(1):80–88., doi:https://doi.org/10.1093/infdis/jis646.
- Hoagland RJ. The transmission of infectious mononucleosis. Am J Med Sci. 1955;229(3):262–272. doi:https://doi.org/10.1097/00000441-195503000-00003.
- Macsween KF, Higgins CD, McAulay KA, et al. Infectious mononucleosis in university students in the United Kingdom: evaluation of the clinical features and consequences of the disease. Clin Infect Dis. 2010;50(5):699–706. doi:https://doi.org/10.1086/650456.
- Putukian M, O’connor FG, Stricker P, et al. Mononucleosis and athletic participation: an evidence-based subject review. Clin J Sport Med. 2008;18(4):309–315. doi:https://doi.org/10.1097/JSM.0b013e31817e34f8.
- de-Thé G, Day NE, Geser A, et al. Sero-epidemiology of the Epstein–Barr virus: preliminary analysis of an international study—a review. IARC Sci Publ. 1975;11:3–16.
- Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196(12):1749–1753. doi:https://doi.org/10.1086/523813.
- Henle G, Henle W. Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines. Cancer Res. 1967;27(12):2442–2446.
- Melbye M, Ebbesen P, Levine PH, Bennike T. Early primary infection and high Epstein-Barr virus antibody titers in Greenland Eskimos at high risk for nasopharyngeal carcinoma. Int J Cancer. 1984;34(5):619–623. doi:https://doi.org/10.1002/ijc.2910340506.
- Balfour HH, Holman CJ, Hokanson KM, Lelonek MM, et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005;192:1505–1512. doi:https://doi.org/10.1086/491740.
- Grimm-Geris JM, Dunmire SK, Duval LM, et al. Screening for Epstein-Barr virus (EBV) infection status in university freshmen: acceptability of a gingival swab method. Epidemiol Infect. 2019;147:e140. doi:https://doi.org/10.1017/S0950268819000335.
- Grimm JM, Schmeling DO, Dunmire SK, et al. Prospective studies of infectious mononucleosis in university students. Clin Trans Immunol. 2016;5(8):e94. doi:https://doi.org/10.1038/cti.2016.48.
- Balfour HH, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208(8):1286–1293. doi:https://doi.org/10.1093/infdis/jit321.
- Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein–Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43(3):276–282. doi:https://doi.org/10.1086/505400.
- Servat E, Ro BW, Cayatte C, et al. Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo. Vaccine. 2015;33(48):6771–6777. doi:https://doi.org/10.1016/j.vaccine.2015.10.024.